Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Jan 02

filter terms:

Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Citation

Raphael J Landovitz, Sahar Z Zangeneh, Gordon Chau, Beatriz Grinsztejn, Joseph J Eron, Halima Dawood, Manya Magnus, Albert Y Liu, Ravindre Panchia, Mina C Hosseinipour, Ryan Kofron, David A Margolis, Alex Rinehart, Adeola Adeyeye, David Burns, Marybeth McCauley, Myron S Cohen, Judith S Currier. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Jan 02;70(2):319-322